PDUFA date set for idelalisib in lymphoma

Gilead's idelalisib got the all-clear for breakthrough designation for chronic lymphocytic leukemia (CLL), but the FDA is treating the drug like any other therapy when it comes to refractory indolent non-Hodgkin's lymphoma (NHL). BioCentury reports that the FDA set aside September 11 as the PDUFA date for this latter indication.

You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.